1. Home
  2. ELTK vs ACRV Comparison

ELTK vs ACRV Comparison

Compare ELTK & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eltek Ltd.

ELTK

Eltek Ltd.

HOLD

Current Price

$8.15

Market Cap

62.5M

Sector

Technology

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.08

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTK
ACRV
Founded
1970
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Electrical Products
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
62.5M
74.0M
IPO Year
1998
2022

Fundamental Metrics

Financial Performance
Metric
ELTK
ACRV
Price
$8.15
$2.08
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $11.67
AVG Volume (30 Days)
15.8K
★ 295.2K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
★ 2.14%
N/A
EPS Growth
N/A
★ 15.13
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.18
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
$48.71
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.30
$1.27
52 Week High
$11.59
$3.56

Technical Indicators

Market Signals
Indicator
ELTK
ACRV
Relative Strength Index (RSI) 47.84 54.90
Support Level $7.62 $2.07
Resistance Level $9.34 $2.21
Average True Range (ATR) 0.53 0.13
MACD 0.01 0.01
Stochastic Oscillator 31.42 73.68

Price Performance

Historical Comparison
ELTK
ACRV

About ELTK Eltek Ltd.

Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: